HBV-TCR-T cells

HBV-TCR-T cells are autologous T cells genetically engineered to transiently express a T cell receptor (TCR) specific for hepatitis B virus (HBV) antigens, particularly the complex of human leukocyte antigen (HLA)-A2 molecule and the S domain region 20–28 of HBV surface antigen. These cells are designed to target and kill both HBV-infected hepatocytes and hepatocellular carcinoma (HCC) cells expressing HBV antigens. The TCRs are typically introduced into the patient’s T cells using transient expression (such as mRNA electroporation) or, in some cases, lentiviral transduction. This immunotherapy has shown safety and preliminary efficacy in phase 1 trials for advanced HBV-related HCC, with observed reductions in serum HBsAg and HBV DNA levels and tumor shrinkage in some patients. The main mechanism is recognition and specific killing of HBV-antigen–presenting cells, with potential secondary immunomodulatory effects in the tumor microenvironment[1][2].

Other names

HBV-specific TCR-engineered T cellsHBV-specific TCR redirected T cells